ALQGC — Quantum Genomics SA Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual income statement for Quantum Genomics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | FAS | FAS | FAS | FAS | FAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 1.2 | 0.116 | 0.605 | 0.01 |
Cost of Revenue | |||||
Gross Profit | -7.89 | -12.1 | -18.3 | -28.9 | -1.43 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 10.6 | 14.9 | 19.3 | 27.7 | 3.19 |
Operating Profit | -10.6 | -13.7 | -19.2 | -27.1 | -3.18 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -10.6 | -13.7 | -19.2 | -27.5 | -3.21 |
Provision for Income Taxes | |||||
Net Income After Taxes | -9.08 | -11.5 | -16.6 | -24.9 | -3.17 |
Net Income Before Extraordinary Items | |||||
Net Income | -9.08 | -11.5 | -16.6 | -24.9 | -3.17 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -9.08 | -11.5 | -16.6 | -24.9 | -3.17 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.507 | -0.436 | -0.603 | -0.771 | -0.09 |
Dividends per Share |